Sai Parenterals reports consolidated loss of Rs 1.11 crore for quarter ended December 2025

The company reported a consolidated net loss of Rs 1.11 crore for the quarter ended December 31, 2025, according to the unaudited financial results approved by the board on May 23, 2026. This performance comes as the entity manages significant capital movements related to its recent international expansion. The consolidated revenue from operations for the same period stood at Rs 163.10 crore, reflecting the scale of its current business activities. The board also reviewed and approved the audited financial results for the full year ended March 31, 2026.

Standalone operations showed a different trend with a reported profit after tax of Rs 0.36 crore for the quarter ended December 31, 2025. The standalone revenue from operations reached Rs 38.48 crore during this three-month period. Total expenses for the standalone entity were recorded at Rs 38.23 crore, which included a cost of materials consumed amounting to Rs 23.88 crore. The basic earnings per share for the standalone quarter was reported at Rs 0.01 per share.

Management highlighted significant strategic investments made through its wholly owned subsidiary, Sai Parenterals Pte Limited. The company completed the acquisition of a 74.64% controlling stake in Noumed Life Sciences Limited (UK) for an aggregate consideration of AUD 2200 million. This transaction included a primary infusion of AUD 4.00 million into the UK-based entity. Following the September 30, 2025 milestone, the company invested equity into its subsidiary to facilitate the completion of this major acquisition.

The statutory auditors, M/s. RKabra & Co. LLP, issued an unmodified opinion on the audited financial results for the year ended March 31, 2026. This declaration confirms that the financial statements present a true and fair view of the company's position. The company is currently engaged in the business of branded generic formulations and Contract Development and Manufacturing Organisation services. It has also filed a Draft Red Herring Prospectus in connection with its proposed Initial Public Offer.

Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.